Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Eiger Biopharmaceuticals
Eiger Biopharmaceuticals
(EIGR)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Zokinvy
Lonafarnib
2022-07-18
2023-2024
Progeria
,
Laminopathies
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Lonafarnib
chronic hepatitis
,
progeria
,
chronic hepatitis d
,
hepatitis d
,
hepatitis
,
virus diseases
,
hepatitis a
,
laminopathies
Ademetionine
heart failure
Alfacalcidol
chronic hepatitis d
,
hepatitis d
,
hepatitis
Avexitide
hypoglycemia
,
congenital hyperinsulinism
,
nesidioblastosis
Sodium chloride
heart failure
,
covid-19
,
cardiomyopathies
,
infections
,
communicable diseases
,
dilated cardiomyopathy
Clemizole
hepatitis c
,
hepatitis
,
hepatitis a
Ubenimex
hypertension
,
pulmonary arterial hypertension
,
familial primary pulmonary hypertension
,
lymphedema
Fendrix
chronic hepatitis d
,
hepatitis d
,
hepatitis
,
virus diseases
,
hepatitis a
Ebp921
hepatitis d
,
hepatitis
,
hepatitis a
Mevalotin
progeria
Exendin9
hypoglycemia
,
congenital hyperinsulinism
,
nesidioblastosis
Ssri
covid-19
,
severe acute respiratory syndrome-related coronavirus
,
severe acute respiratory syndrome
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use